This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
A United Nations-backed organization working to cut the price of HIV drugs said it had signed a deal with Bristol-Myers Squibb Co to allow generic versions of the company’s hepatitis C drug to be sold in 112 low- and middle-income countries.
The Medicines Patent Pool said on Monday that Daklinza would now be available to nearly two-thirds of people affected by the disease in low- and middle-income countries.
The list price in the United States for Daklinza is $63,000 for a 12-week regimen, or about $750 per day at wholesale costs, according to pharmacy benefits manager Express Scripts.
Other drugs used to treat hepatitis C include Gilead Sciences’ Sovaldi. A single Sovaldi pill costs $1,000 in the United States, according to Express Scripts.
The deal with Bristol-Myers allows drugmakers anywhere in the world to develop generic versions of Daklinza.
Read more at Reuters http://www.reuters.com/article/2015/11/23/us-bristol-myers-hepatitis-idUSKBN0TC1GD20151123#jfF0pYH3Ke8gRxl3.99